BiomX Inc. PHGE
are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target
and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI.
Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are
considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and by creating novel phage using
Last close
1.85
2026-09-10
Market cap
$49.4M
2026-06-30 share count
52-week range
0.12 - 11.51
Valuation FY2025 figures against the last close
P/S—
P/E0.1x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS22.19
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $21.3M | $24.7M | $16.7M | $16.2M | $22.7M | $19.4M | $13.5M | $9.1M | — |
| SG&A | $9.6M | $11.8M | $8.7M | $9.5M | $11.3M | $9.3M | $8.7M | $3.4M | — |
| Total operating expenses | — | — | — | $376.0K | — | — | — | — | — |
| Operating income | -$41.5M | -$44.5M | -$25.3M | -$27.2M | -$35.5M | -$30.3M | -$22.2M | -$12.5M | — |
| Interest expense | $20.0K | $873.0K | $2.4M | $2.1M | $699.0K | — | — | — | — |
| Pre-tax income | -$36.2M | -$17.7M | -$26.1M | -$28.3M | -$36.2M | -$30.1M | -$20.6M | -$12.7M | — |
| Income tax | $7.0K | $13.0K | $23.0K | $65.0K | $67.0K | — | $135.2K | — | — |
| Net income | -$36.2M | -$17.7M | -$26.2M | -$28.3M | -$36.2M | -$30.1M | -$20.6M | -$12.7M | — |
| EPS, basic | 22.19 | 25.37 | 5.10 | 0.95 | 1.39 | — | — | — | — |
| EPS, diluted | 22.19 | 58.31 | 5.10 | 0.95 | 1.39 | 1.30 | 3.66 | 7.62 | — |
| Shares, diluted (wtd. avg.) | 1.6M | 757,749 | 5.1M | 29.9M | 26.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.4M | $16.9M | $15.9M | $32.3M | $63.1M | $37.2M | $72.4M | $8.7M | $7.0M |
| Short-term investments | — | — | — | $2.0M | — | $19.9M | $10.0M | $31.1M | — |
| Total current assets | $5.6M | $20.5M | $17.6M | $36.9M | $66.6M | $60.7M | $84.5M | $39.9M | — |
| Property, plant and equipment | — | $5.0M | $3.9M | $4.8M | $5.7M | $2.2M | $1.9M | $887.0K | — |
| Goodwill | — | $801.0K | — | — | — | — | — | — | — |
| Other intangibles | — | — | — | — | $1.5M | $3.0M | — | — | — |
| Total assets | $5.8M | $43.2M | $25.0M | $45.5M | $78.0M | $70.4M | $92.1M | $45.3M | — |
| Accounts payable | — | — | — | $820.0K | $2.8M | $2.3M | $3.3M | $193.0K | — |
| Short-term debt | — | — | $5.8M | $4.3M | — | — | $375.0K | — | — |
| Total current liabilities | $6.4M | $8.3M | $11.2M | $7.9M | $11.0M | $7.2M | $6.2M | $1.6M | — |
| Long-term debt | — | — | $5.4M | $10.6M | $14.4M | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | $871.0K | $41.0K | — |
| Retained earnings | -$216.9M | -$180.7M | -$163.0M | -$136.8M | — | — | $346.4K | -$1.0K | — |
| Total equity | -$1.3M | $24.1M | $3.1M | $21.0M | $47.5M | $57.5M | $84.5M | $42.8M | $11.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.4M | -$37.0M | -$21.3M | -$29.1M | -$27.6M | -$24.4M | -$17.6M | -$11.3M | — |
| Depreciation and amortisation | $2.9M | $1.8M | $871.0K | $909.0K | $986.0K | -$1.3M | $318.0K | $210.0K | — |
| Stock-based compensation | $2.1M | $1.8M | $1.1M | $1.5M | $3.2M | $2.9M | $938.0K | $951.0K | — |
| Capital expenditure | $2.0K | $30.0K | $50.0K | $112.0K | $3.7M | $1.0M | $1.3M | $137.0K | — |
| Investing cash flow | $108.0K | $715.0K | $2.0M | -$2.1M | $16.2M | -$10.9M | $19.7M | -$30.0M | — |
| Financing cash flow | $13.2M | $38.4M | $2.9M | $292.0K | $37.3M | $134.0K | $61.6M | $43.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050373.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$12.7M | -$20.6M | -$30.1M | -$36.2M | -$28.3M | -$26.2M | -$17.7M | -$36.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Other event Item 8.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Shareholder vote Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |